Up­dat­ed: Dif­fer­ent way to go af­ter KRAS mu­tant tu­mors? No­vo-backed biotech nabs $50M to wrap ear­ly stud­ies

Am­gen and Mi­rati may be duk­ing it out over who gets to set the stan­dard of care in KRAS mu­tant can­cer, but a small com­pa­ny be­lieves it can of­fer an even more pow­er­ful al­ter­na­tive.

That promise is draw­ing new in­vestors to In­spir­na, which has just bagged a $50 mil­lion Se­ries D to push for­ward its lead small mol­e­cule drug in RAS mu­tant ad­vanced col­orec­tal can­cer. A sec­ond can­di­date is be­ing test­ed to treat lung can­cer and en­dome­tri­al can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER